$3.00
▲ +0.7% Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
Is Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires?
Overview
52-week range
$2.77
$7.18
5% of range
Avg surprise (last 3)
-1.4%
Avg reaction (last 2)
-7.4%
50% positive
Latest IV / EM
94%
EM ±5.5% · $3 · Jul 24
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $-0.22 | $-0.30 | +26.7% | +56.0% | +1.8% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.36 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-0.41 | $-0.35 | -17.1% | — | — | earnings |
| Mon May 5, 2025 | Mar/2025 | $-0.50 | $-0.44 | -13.6% | — | -16.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.34 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.40 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.39 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.43 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.38 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | OTHER | -$0.25 | -$0.41 | +39.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6M | — | $5M | $19M | $15M | — | $26M | $14M |
| Cost of revenue | $12M | — | $15M | $20M | $22M | — | $12M | $9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-129M | — | $-172M | $-176M | $-191M | — | $-98M | $-101M |
| Net income | $-118M | — | $-162M | $-172M | $-202M | — | $-96M | $-98M |
| EPS (diluted) | $-0.22 | — | $-0.36 | $-0.41 | $-0.50 | — | $-0.34 | $-0.40 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $654M | $743M | $660M | $525M | $500M | $594M | $428M | $474M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $710M | $813M | $714M | $587M | $584M | $714M | $474M | $522M |
| Total assets | $1.34B | $1.47B | $1.40B | $1.30B | $1.31B | $1.45B | $726M | $776M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $315M | $343M | $353M | $383M | $371M | $414M | $202M | $191M |
| Total equity | $1.02B | $1.13B | $1.05B | $919M | $934M | $1.03B | $525M | $584M |